SAVA MEXC RealStocks
Own real SAVA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 07:02:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cassava Sciences, Inc. (SAVA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- |
Cassava Sciences, Inc. (SAVA) last closed at $-- as of --, -- from the previous close of $--.
During the latest regular trading session, SAVA traded between $-- and $--, with a volume of -- shares. The closing price was -- and --.
Over the past seven days, Cassava Sciences, Inc. (SAVA) moved from $2.20 to $2.38, representing a gain of 8.18% ($0.18).
The stock traded between $1.96 and $2.49 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 867.30 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 30 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Cassava Sciences, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Dec 13, 2012 |
| Payment Date | Dec 24, 2012 |
| Dividend Per Share | $0.75 |
Eligible investors can buy real shares of Cassava Sciences, Inc. (SAVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to SAVA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between SAVA shares and USD.
SAVA Shares to USD
1.00 SAVA shares = 0 USD
Calculations are estimates based on the latest available price and are for reference only.